Roberto Ferrarese

Dr. Roberto Ferrarese


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2022 in Viruses
Verified
Journal Article
Open access
PDF file
ALAlessia Lai
Alessia Lai
ABAnnalisa Bergna
Annalisa Bergna
CVCarla della Ventura
Carla della Ventura
Stefano MenzoStefano Menzo
Stefano Menzo
BBBianca Bruzzone
Bianca Bruzzone
SGSARS-CoV- ITALIAN RESEARCH ENTERPRISE–(SCIRE) Collaborative Group
SARS-CoV- ITALIAN RESEARCH ENTERPRISE–(SCIRE) Collaborative Group
SARS-CoV-2 is constantly evolving, leading to new variants. We analysed data from 4400 SARS-CoV-2-positive samples in order to pursue epidemiological variant surveillance and to evaluate their impact on public health in Italy in the period of April–December 2021. The main circulating strain (76.2%) was the Delta variant, followed by the Alpha (13.3%), the Omicron (5.3%), and the Gamma variants (2.9%). The B.1.1 lineages, Eta, Beta, Iota, Mu, and Kappa variants, represented around 1% of cases. There were 48.2% of subjects who had not been vaccinated, and they had a lower median age compared to the vaccinated subjects (47 vs. 61 years). An increasing number of infections in the vaccinated subjects were observed over time, with the highest proportion in November (85.2%). The variants correlated with clinical status; the largest proportion of symptomatic patients (59.6%) was observed with the Delta variant, while subjects harbouring the Gamma variant showed the highest proportion of asymptomatic infection (21.6%), albeit also deaths (5.4%). The Omicron variant was only found in the vaccinated subjects, of which 47% had been hospitalised. The diffusivity and pathogenicity associated with the different SARS-CoV-2 variants are likely to have relevant public health implications, both at the national and international levels. Our study provides data on the rapid changes in the epidemiological landscape of the SARS-CoV-2 variants in Italy.

24 August 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RFRoberto Ferrarese
Roberto Ferrarese
RZRaffaella Alessia Zuppardo
Raffaella Alessia Zuppardo
MPMarta Puzzono
Marta Puzzono
Alessandro MannucciAlessandro Mannucci
Alessandro Mannucci
VAVirginia Amato
Virginia Amato
Giulia Martina CavestroGiulia Martina Cavestro
Giulia Martina Cavestro
Background: The role of microbiota in Lynch syndrome (LS) is still under debate. We compared oral and fecal microbiota of LS saliva and stool samples with normal healthy controls (NHC). Methods: Total DNA was purified from feces and saliva to amplify the V3–V4 region of the 16s rRNA gene. Sequences with a high-quality score and length >250 bp were used for taxonomic analysis with QIIME software. Results: Compared to NHC, LS fecal samples demonstrated a statistically significant increase of Bacteroidetes and Proteobacteria and a significant decrease of Firmicutes at the phylum level and of Ruminococcaceae at the family level. Moreover, LS oral samples exhibited a statistically significant increase of Veillonellaceae and Leptotrichiaceae and a statistically significant decrease of Pasteurellaceae. A beta-diversity index allowed differentiation of the two groups. Conclusions: A peculiar microbial signature is associated with LS, similar to that of sporadic colorectal cancer and Crohn’s disease. These data suggest a possible role of proinflammatory bacteria in tumor development in a condition of genetic predisposition, such as LS.

31 July 2021 in Viruses
Verified
Journal Article
Open access
PDF file
MCMatteo Castelli
Matteo Castelli
Andreina BajAndreina Baj
Andreina Baj
Elena CriscuoloElena Criscuolo
Elena Criscuolo
RFRoberto Ferrarese
Roberto Ferrarese
Roberta Antonia DiottiRoberta Antonia Diotti
Roberta Antonia Diotti
NMNicasio Mancini
Nicasio Mancini
SARS-CoV-2 spike is evolving to maximize transmissibility and evade the humoral response. The massive genomic sequencing of SARS-CoV-2 isolates has led to the identification of single-point mutations and deletions, often having the recurrence of hotspots, associated with advantageous phenotypes. We report the isolation and molecular characterization of a SARS-CoV-2 strain, belonging to a lineage (C.36) not previously associated with concerning traits, which shows decreased susceptibility to vaccine sera neutralization.

16 September 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
ALAlessia Lai
Alessia Lai
ABAnnalisa Bergna
Annalisa Bergna
CVCarla della Ventura
Carla della Ventura
Stefano MenzoStefano Menzo
Stefano Menzo
BBBianca Bruzzone
Bianca Bruzzone
Gianguglielmo ZehenderGianguglielmo Zehender
Gianguglielmo Zehender
SARS-CoV-2 is constantly evolving leading to new variants. We analysed data from 4,400 SARS-CoV-2-positive samples in order to continue variant surveillance in Italy to evaluate their epidemiological and relative impact on public health in the period April-December 2021. The main circulating strain (76.2%) was Delta followed by Alpha (13.3%), Omicron (5.3%) and Gamma variants (2.9%). B.1.1 lineages, Eta, Beta, Iota, Mu and Kappa variants represented around 1% of cases. Overall, 48.2% of subjects were not vaccinated with a lower median age compared to vaccinated subjects (47 vs. 61 years). An increasing number of infections in vaccinated subjects was observed overtime, with the highest proportion in November (85.2%). Variants correlated with clinical status; the largest proportion of symptomatic patients (59.6%) was observed among Delta variant, while subjects harboring Gamma variant showed the highest proportion of asymptomatics (21.6%), albeit also of deaths (5.4%). The Omicron variant was only found in vac-cinated subjects, of which 47% were hospitalized. Diffusivity and pathogenicity associated with the different SARS-CoV-2 variants are likely to have relevant public health implications, both at national and international level. Our study pro-vides data on the rapid changes in the epidemiological landscape of SARS-CoV-2 variants in Italy.

31 March 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
Nicola ClementiNicola Clementi
Nicola Clementi
Elena CriscuoloElena Criscuolo
Elena Criscuolo
Roberta Antonia DiottiRoberta Antonia Diotti
Roberta Antonia Diotti
RFRoberto Ferrarese
Roberto Ferrarese
MCMatteo Castelli
Matteo Castelli
NMNicasio Mancini
Nicasio Mancini
While the SARS-CoV-2 pandemic is hardly hitting the world, it is of extreme importance that significant in vitro observations guide the quick set up of clinical trials. In this study, we evidence that the anti-SARS-CoV2 activity of a clinically achievable hydroxychloroquine concentration is maximized only when administered before and after the infection of Vero E6 cells. This strongly suggests that only a combined prophylactic and therapeutic use of hydroxychloroquine may be effective in limiting viral replication in patients.

7 June 2022 in Viruses
Verified
Journal Article
Open access
PDF file
Elena CriscuoloElena Criscuolo
Elena Criscuolo
BGBenedetta Giuliani
Benedetta Giuliani
DFDavide Ferrari
Davide Ferrari
RFRoberto Ferrarese
Roberto Ferrarese
Roberta Antonia DiottiRoberta Antonia Diotti
Roberta Antonia Diotti
Nicola ClementiNicola Clementi
Nicola Clementi
(1) Background: Our aim is the evaluation of the neutralizing activity of BNT162b2 mRNA vaccine-induced antibodies in different in vitro cellular models, as this still represents one of the surrogates of protection against SARS-CoV-2 viral variants. (2) Methods: The entry mechanisms of SARS-CoV-2 in three cell lines (Vero E6, Vero E6/TMPRSS2 and Calu-3) were evaluated with both pseudoviruses and whole virus particles. The neutralizing capability of sera collected from vaccinated subjects was characterized through cytopathic effects and Real-Time RT PCR. (3) Results: In contrast to Vero E6 and Vero E6/TMPRSS2, Calu-3 allowed the evaluation of both viral entry mechanisms, resembling what occurs during natural infection. The choice of an appropriate cellular model can decisively influence the determination of the neutralizing activity of antibodies against SARS-CoV-2 variants. Indeed, the lack of correlation between neutralizing data in Calu-3 and Vero E6 demonstrated that testing the antibody inhibitory activity by using a single cell model possibly results in an inaccurate characterization. (4) Conclusions: Cellular systems allowing only one of the two viral entry pathways may not fully reflect the neutralizing activity of vaccine-induced antibodies moving increasingly further away from possible correlates of protection from SARS-CoV-2 infection.